PureTech Healths’s Gelesis treats final patient for loss of weight study

July 12, 2017 Off By Dino Mustafić

Gelesis Inc, a subsidiary of PureTech Health, has completed treatment of the final patient in the pivotal GLOW (Gelesis Loss Of Weight) Study, to assess the long-term efficacy and safety of its Gelesis100.

The study is designed over a six-month period across a broad patient population. Results from this registration-enabling trial are expected in Q3 2017.

PureTech also said that Gelesis has enrolled its first European patient in the ongoing LIGHT-UP study with its second product candidate, Gelesis200, for weight loss and glycaemic control. LIGHT-UP will enrol individuals across the United States, Canada, and Europe who are overweight or have obesity and also have prediabetes or metformin-treated type 2 diabetes.

Dr. Bharatt Chowrira, President and Chief of Business and Strategy at PureTech Health, said: “As a result of new, preclinical research and the pioneering work of Gelesis in this emerging field of mechanobiology, we are also planning or initiating pilot studies across a number of additional indications including early nonalcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD), and other gastrointestinal disorders.”